BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced upcoming presentations at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025 in Seattle. The company will present Phase 2 data for encaleret in post-surgical hypoparathyroidism through an oral presentation by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research.

Additionally, two poster sessions focusing on skeletal dysplasia research will be presented by Dr. Bhavik Shah, showcasing data on infigratinib's effects on bone growth in hypochondroplasia and skull measures in Crouzon/Pfeiffer Syndromes mouse models.

PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025.

Post-Surgical Hypoparathyroidism Oral Presentation:
The Oral Calcilytic Encaleret Reduced Urinary Calcium While Maintaining Blood Calcium in Individuals with Post-Surgical Hypoparathyroidism
Presenter: Iris Hartley, M.D., National Institute of Dental and Craniofacial Research, National Institutes of Health
Date/time: Saturday, September 6 at 11:30 am PT

Skeletal Dysplasia Poster Sessions:
Infigratinib Low Dose Therapy Is an Effective Strategy in Improving Bone Growth in a Hypochondroplasia Mouse Model
Presenter: Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBio
Date/time: Friday, September 5 at 5:00 pm PT and Sunday, September 7 at 2:00 pm PT

Infigratinib Improves Skull Measures in a Mouse Model of Crouzon/Pfeiffer Syndromes
Presenter: Bhavik Shah, Ph.D., Senior Vice President of Research, Genetic Medicine, Skeletal Dysplasia, BridgeBio
Date/time: Saturday, September 6 at 2:00 pm PT

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com  

FAQ

When will BridgeBio (BBIO) present its Phase 2 encaleret data at ASBMR 2025?

BridgeBio will present the Phase 2 encaleret data on Saturday, September 6, 2025, at 11:30 am PT during the ASBMR Annual Meeting in Seattle.

What is the focus of BridgeBio's (BBIO) encaleret Phase 2 presentation?

The presentation focuses on how the oral calcilytic encaleret reduced urinary calcium while maintaining blood calcium in individuals with post-surgical hypoparathyroidism.

What skeletal dysplasia research is BridgeBio (BBIO) presenting at ASBMR 2025?

BridgeBio is presenting research on infigratinib's effects on bone growth in hypochondroplasia and its impact on skull measures in Crouzon/Pfeiffer Syndromes through poster sessions.

Who are the key presenters for BridgeBio (BBIO) at ASBMR 2025?

The key presenters are Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research for the encaleret presentation, and Dr. Bhavik Shah, Senior VP of Research, for the skeletal dysplasia sessions.